Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

被引：11

作者：

Zeidan, Amer M. ^{[1
,2
]}

Schuster, Michael W. ^{[3
]}

Krauter, Jurgen ^{[4
]}

Maertens, Johan A. ^{[5
]}

Gyan, Emmanuel ^{[6
]}

Joris, Magalie ^{[7
]}

Menne, Tobias F. ^{[8
]}

Vyas, Paresh ^{[9
]}

Ma, Weidong Wendy ^{[10
]}

O'Connell, Ashleigh ^{[10
]}

Zeremski, Mirjana ^{[10
]}

Kudla, Arthur ^{[10
]}

Chan, Geoffrey

Sekeres, Mikkael A. ^{[11
]}

机构：

[1] Yale Sch Med, New Haven, CT USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Stony Brook Univ Hosp, Canc Ctr, Stony Brook, NY USA

[4] Med Klinikum Braunschweig GmbH, Dept Internal Med 3, Braunschweig, Germany

[5] UZ Leuven, Leuven, Belgium

[6] CHU Tours, Hop Bretonneau, Tours, France

[7] CHU Amiens Picardie, Amiens, France

[8] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Haematol, Newcastle Upon Tyne, Tyne & Wear, England

[9] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England

[10] Pfizer Oncol, New York, NY USA

[11] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124034

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3916

引用

页数：5

共 50 条

[31] Arsenic Trioxide and Low-dose Cytarabine in Older Patients With Untreated Acute Myeloid Leukemia, Excluding Acute Promyelocytic Leukemia [J].

Roboz, Gail J. ;

Ritchie, Ellen K. ;

Curcio, Tania ;

Provenzano, Juliette ;

Carlin, Rebecca ;

Samuel, Michael ;

Wittenberg, Beth ;

Mazumdar, Madhu ;

Christos, Paul J. ;

Mathew, Susan ;

Allen-Bard, Sandra ;

Feldman, Eric J. .

CANCER, 2008, 113 (09) :2504-2511

[32] MAINTENANCE WITH LOW-DOSE CYTARABINE FOR ACUTE MYELOID-LEUKEMIA IN COMPLETE REMISSION [J].

ARCHIMBAUD, E ;

ANGLARET, B ;

THOMAS, X ;

JAUBERT, J ;

SEBBAN, C ;

GUYOTAT, D ;

FIERE, D .

ANNALS OF HEMATOLOGY, 1992, 65 (02) :71-74

[33] The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada [J].

Hu, Yannan ;

Charaan, Majed ;

van Oostrum, Ilse ;

Heeg, Bart ;

Bell, Timothy .

JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) :150-161

[34] Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia [J].

Ramakrishnan, Ramya ;

Munir, Faryal ;

Quesada, Andres Ernesto ;

Hitzler, Johann ;

Cuglievan, Branko .

PEDIATRIC BLOOD & CANCER, 2024, 71 (06)

[35] Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia [J].

Martinez-Cuadron, David ;

Montesinos, Pau ;

Oriol, Albert ;

Salamero, Olga ;

Vidriales, Belen ;

Bergua, Juan ;

Herrera, Pilar ;

Vives, Susanna ;

Sanz, Jaime ;

Carpio, Cecilia ;

Rodriguez-Veiga, Rebeca ;

Moscardo, Federico ;

Sanz, Miguel A. .

ANNALS OF HEMATOLOGY, 2014, 93 (01) :43-46

[36] Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia [J].

David Martínez-Cuadrón ;

Pau Montesinos ;

Albert Oriol ;

Olga Salamero ;

Belén Vidriales ;

Juan Bergua ;

Pilar Herrera ;

Susanna Vives ;

Jaime Sanz ;

Cecilia Carpio ;

Rebeca Rodríguez-Veiga ;

Federico Moscardó ;

Miguel A. Sanz .

Annals of Hematology, 2014, 93 :43-46

[37] Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial. [J].

Smith, B. Douglas ;

Papayannidis, Cristina ;

Heuser, Michael ;

Montesinos, Pau ;

Sekeres, Mikkael A. ;

Oriol, Albert ;

Schiller, Gary J. ;

Candoni, Anna ;

Jamieson, Catriona H. M. ;

Hoang, Caroline J. ;

Ma, Wendy ;

Zeremski, Mirjana ;

O'Connell, Ashleigh ;

Chan, Geoffrey ;

Cortes, Jorge E. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[38] Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients [J].

Faderl, Stefan ;

Ravandi, Farhad ;

Huang, Xuelin ;

Wang, Xuemei ;

Jabbour, Elias ;

Garcia-Manero, Guillermo ;

Kadia, Tapan ;

Ferrajoli, Alessandra ;

Konopleva, Marina ;

Borthakur, Gautam ;

Burger, Jan ;

Feliu, Jennie ;

Kantarjian, Hagop M. .

CANCER, 2012, 118 (18) :4471-4477

[39] Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (vol 100, pg 1181, 2021) [J].

Heuser, Michael ;

Smith, B. Douglas ;

Fiedler, Walter ;

Sekeres, Mikkael A. ;

Montesinos, Pau ;

Leber, Brian ;

Merchant, Akil ;

Papayannidis, Cristina ;

Perez-Simon, Jose A. ;

Hoang, Caroline J. ;

O'Brien, Thomas ;

Ma, Weidong Wendy ;

Zeremski, Mirjana ;

O'Connell, Ashleigh ;

Chan, Geoffrey ;

Cortes, Jorge E. .

ANNALS OF HEMATOLOGY, 2021, 100 (07) :1917-1918

[40] A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy [J].

Solem, Caitlyn T. ;

Bell, Timothy J. ;

Kwon, Youngmin ;

Cappelleri, Joseph C. ;

Johnson, Courtney ;

Bhattacharyya, Helen ;

Hoang, Caroline J. ;

Cortes, Jorge E. .

CANCER, 2020, 126 (19) :4315-4321

← 1 2 3 4 5 →